Journal of Medical Economics最新文献

{"title":"Cost-utility analysis of icosapent ethyl in patients with high triglyceride levels and recent acute coronary syndrome in Catalonia.","authors":"Josep Comin-Colet, Román Freixa, Nuria García-Muñoz, Maria Mallén-Alberdi, Javier Montaño, Sabine Gaugris, Chetan Mistry, Laurence Tilley, Gustavo Vitale, Salvador López","doi":"10.1080/13696998.2025.2557717","DOIUrl":"https://doi.org/10.1080/13696998.2025.2557717","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the cost-effectiveness of icosapent ethyl (IPE) as an adjunct to standard of care (SoC) for reducing cardiovascular (CV) events in statin-treated adults with elevated triglycerides (TG ≥ 150 mg/dL), established CV disease, and a recent acute coronary syndrome (ACS) in Catalonia, Spain.</p><p><strong>Methods: </strong>A <i>de-novo</i> partitioned survival model was developed to simulate the natural history of CV events over a 20-year horizon from the Catalan healthcare payer perspective. The model incorporated clinical efficacy and safety data from a <i>post-hoc</i> analysis of REDUCE-IT, a global CV outcomes trial with IPE, local treatment patterns, and Spanish-specific cost data. Outcomes were expressed in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICERs). Deterministic, probabilistic, and scenario sensitivity analyses were conducted to assess model robustness.</p><p><strong>Results: </strong>In the base case, IPE plus SoC resulted in an incremental gain of 0.57 QALYs and €8,287 in additional costs compared to SoC alone, yielding an ICER of €14,543/QALY gained-well below the commonly accepted willingness-to-pay threshold of €30,000/QALY in Spain. Probabilistic sensitivity analysis showed that IPE was cost-effective in 75.3% of simulations and dominant in 15.4%. Scenario analyses confirmed the robustness of results across different time horizons and discount rates. Key drivers of cost-effectiveness were the selected efficacy curves for IPE and its per-cycle treatment cost.</p><p><strong>Conclusions: </strong>IPE appears to be a cost-effective intervention for high-risk patients with elevated TG and recent ACS in Catalonia. While limitations related to model assumptions, data extrapolation, and partial adaptation to local clinical practice exist, the findings remain consistent with international evidence and suggest that IPE could be a cost-effective intervention in Catalonia, offering a valuable opportunity to optimize healthcare resource allocation in the management of high-risk CV populations.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"28 1","pages":"1574-1590"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145075096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of healthcare resource utilization and direct medical cost in relation to treatment length of oral corticosteroids in biologic-initiated patients with ulcerative colitis: a Japanese claims database study.","authors":"Celine Miyazaki, Tomoyuki Inoue, Shinya Sugimoto, Shinichi Yoshigoe, Nan Li","doi":"10.1080/13696998.2025.2555138","DOIUrl":"10.1080/13696998.2025.2555138","url":null,"abstract":"<p><strong>Background: </strong>Ulcerative colitis (UC) imposes persistent clinical and economic burden on patient and healthcare management in Japan.</p><p><strong>Purpose: </strong>To evaluate impact of prolonged oral corticosteroid (OC) use on healthcare resource utilization (HCRU) and treatment-related costs, and to assess discontinuation patterns of 5-amino salicylic acid (5-ASA), immunomodulators (IMs), and OCs in Japanese UC patients after biologic initiation.</p><p><strong>Methods: </strong>Data were extracted from the Japan Medical Data Centre for patients diagnosed with UC with ≥1 prescription of OC with 5-ASA and/or IM, prior or at the index date (first biologic initiation) between 2016 and 2022, grouped by </≥180 days of OC use, and analyzed using descriptive statistics, Kaplan-Meier and linear regression.</p><p><strong>Results: </strong>For all identified patients (<i>N</i> = 1,494; mean ± SD age: 38.6 ± 13.7 years; male: 65.3%), HCRU (inpatient and outpatient visits, length of stay, and procedures) per patient-year (PPY) declined after biologics initiation. Direct inpatient medical costs decreased throughout the study; outpatient costs increased from pre-index to the 1-year post-index period, followed by slight decrease in the 2-year and 3-year post-index. PPY costs of non-biologic UC-related drugs (OCs, 5-ASA, IMs) increased slightly during the post-index period. Overall, HCRU and costs dynamics were similar in patients with <180 days and those with ≥180 days of OC use. Patients with <180 days of OC use had shorter median time to OC discontinuation after biologic initiation compared with ≥180 days group (3.1 months vs 9.5 months).</p><p><strong>Conclusions: </strong>Biologic initiation was associated with reduced HCRU and inpatient costs, with similar trends observed regardless of prolonged or shorter OC use duration.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"1526-1539"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144992638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the cost-utility of ferric derisomaltose versus ferric carboxymaltose in patients with inflammatory bowel disease and iron deficiency anaemia in Norway.","authors":"T E Detlie, L N Karlsen, E Jørgensen, N Nanu, R F Pollock","doi":"10.1080/13696998.2024.2444833","DOIUrl":"10.1080/13696998.2024.2444833","url":null,"abstract":"<p><strong>Aims: </strong>Iron deficiency anemia (IDA) is among the most common extraintestinal sequelae of inflammatory bowel disease (IBD). Intravenous iron is often the preferred treatment in patients with active inflammation with or without active bleeding, iron malabsorption, or intolerance to oral iron. The aim of the present study was to evaluate the cost-utility of ferric derisomaltose (FDI) versus ferric carboyxymaltose (FCM) in patients with IBD and IDA in Norway.</p><p><strong>Materials and methods: </strong>A published patient-level simulation model was used to evaluate the cost-utility of FDI versus FCM in patients with IBD and IDA from a Norwegian national payer perspective. Iron need was modelled based on bivariate distributions of hemoglobin and bodyweight combined with simplified tables of iron need from the FDI and FCM summaries of product characteristics. Patient characteristics and disease-related quality of life data were obtained from the PHOSPHARE-IBD trial. Cost-utility was evaluated in Norwegian Kroner (NOK) over a five-year time horizon.</p><p><strong>Results: </strong>Patients required 1.64 fewer infusions of FDI than FCM over five years (5.62 versus 7.26), corresponding to 0.41 fewer infusions per treatment course. The reduction in the number of infusions resulted in cost savings of NOK 5,236 (NOK 35,830 with FDI versus NOK 41,066 with FCM). The need for phosphate testing in patients treated with FCM resulted in further cost savings with FDI (no costs with FDI versus NOK 4,470 with FCM). Total cost savings with FDI were therefore NOK 9,707. FDI also increased quality-adjusted life expectancy by 0.071 quality-adjusted life years (QALYs) driven by reduced incidence of hypophosphatemia and fewer interactions with the healthcare system.</p><p><strong>Conclusions: </strong>FDI resulted in cost savings and improved quality-adjusted life expectancy versus FCM in patients with IDA and IBD in Norway. FDI therefore represents the economically preferable iron formulation in Norwegian patients with IBD and IDA in whom it is indicated.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"291-301"},"PeriodicalIF":2.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systematic review of cost-effectiveness modelling studies for haemophilia.","authors":"Niklaus Meier, Daniel Ammann, Mark Pletscher, Jano Probst, Matthias Schwenkglenks","doi":"10.1080/13696998.2024.2444157","DOIUrl":"10.1080/13696998.2024.2444157","url":null,"abstract":"<p><strong>Aims: </strong>Haemophilia is a rare genetic disease that hinders blood clotting. We aimed to review model-based cost-effectiveness analyses (CEAs) of haemophilia treatments, describe the sources of clinical evidence used by these CEAs, summarize the reported cost-effectiveness of different treatment strategies, and assess the quality and risk of bias.</p><p><strong>Methods: </strong>We conducted a systematic literature review of model-based CEAs of haemophilia treatments by searching databases, the Tufts Medical Center CEA registry, and grey literature. We summarized and qualitatively synthesized the approaches and results of the included CEAs, without a meta-analysis due the diversity of the studies.</p><p><strong>Results: </strong>32 eligible studies were performed in 12 countries and reported 53 pairwise comparisons. Most studies analysed patients with haemophilia A rather than haemophilia B. Comparisons of prophylactic versus on-demand treatment indicated that prophylaxis may not be cost-effective, but there was no clear consensus. Emicizumab was generally cost-effective compared with clotting factor treatments and was always dominant for patients with inhibitors. Immune tolerance induction following a Malmö protocol was found to be cost-effective compared to bypassing agents, while there was no consensus for the other protocols. Gene therapies as well as treatment with extended half-life coagulation factors were always cost-effective over their comparators. Studies were highly heterogenous regarding their time horizons, model structures, the inclusion of bleeding-related mortality and quality-of-life impacts. This heterogeneity limited the comparability of the studies. 19 of the 32 included studies received industry funding, which may have biased their results.</p><p><strong>Limitations: </strong>It was not possible to perform a quantitative synthesis of the results due to the heterogeneity of the underlying studies.</p><p><strong>Conclusion: </strong>Differences in results between previous CEAs may have been driven by heterogeneity in modelling approaches, clinical input data, and potential funding biases. A more consistent evidence base and modelling approach would enhance the comparability between CEAs.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"89-104"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children.","authors":"Ahuva Averin, Derek Weycker, Rotem Lapidot, Mark H Rozenbaum, Liping Huang, Jeffrey Vietri, Adriano Arguedas Mohs, Alejandro Cane, Alexander Lonshteyn, Stephen I Pelton","doi":"10.1080/13696998.2025.2484919","DOIUrl":"10.1080/13696998.2025.2484919","url":null,"abstract":"<p><strong>Background: </strong>Invasive pneumococcal disease (IPD), pneumonia (PNE), and otitis media (OM) are significant causes of morbidity among children in the United States (US). While studies have evaluated the economic burden of these conditions, recent data on episodic costs of IPD, PNE, and OM requiring hospitalization or ambulatory care only among US children by age and comorbidity profile are currently not available. This study was undertaken to address this evidence gap.</p><p><strong>Methods: </strong>A retrospective observational cohort design and data (2015-2019) from Optum's de-identified Clinformatics^® Data Mart Database were employed. Episodes of IPD, all-cause PNE, and all-cause OM were ascertained on a monthly basis during the follow-up period and stratified by care setting (hospital vs. ambulatory); all-cause OM was alternatively stratified by disease severity (acute, persistent, tympanostomy tube placement) and, for acute/persistent, by complexity (simple, complex). Mean episodic costs of disease were estimated for children aged <1, 1-<2, 2-<6, and 6-<18 years, respectively, overall and by comorbidity profile (with vs. without ≥1 medical condition).</p><p><strong>Results: </strong>Mean age-specific cost of IPD hospitalization ranged from $40,575-$95,607; IPD requiring care in an emergency department (ED), from $2,013-$5,606; and IPD requiring care in other ambulatory settings, from $619-$1,103. Mean cost of all-cause PNE ranged from $16,631-$21,429 for hospitalized cases; $2,462-$2,685 for ED cases; and $424-$473 for other ambulatory cases. Corresponding ranges for all-cause OM were $14,599-$16,341; $1,190-$2,083; and $253-$514. Children with (vs. without) comorbidities had higher mean costs of PNE episodes across all ages and care settings; mean cost of all-cause OM was largely invariant by comorbidity profile and was highest for episodes involving TTP.</p><p><strong>Conclusions: </strong>Costs of IPD, all-cause PNE, and all-cause OM are high, particularly in the hospital setting. All-cause PNE, one of the most common causes of hospitalization for children, is particularly costly for children with comorbidities.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"517-523"},"PeriodicalIF":2.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143730414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One man's waste is another man's treasure: the case of wastewater-based Respiratory Syncytial Virus surveillance's efficiency.","authors":"Panagiotis Petrou, Christos Petrou","doi":"10.1080/13696998.2025.2539641","DOIUrl":"10.1080/13696998.2025.2539641","url":null,"abstract":"","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"1319-1321"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Economic value of intra-articular knee OA therapies: a U.S. perspective.","authors":"Vinod Dasa, Wilson Ngai, Kevin Steele, Ronald Preblick, Heather Watson, Kevin L Ong","doi":"10.1080/13696998.2025.2549629","DOIUrl":"10.1080/13696998.2025.2549629","url":null,"abstract":"<p><strong>Aims: </strong>This study compared the six-month medical/pharmacy costs and healthcare resource utilization (HCRU) for knee OA patients undergoing intra-articular therapy with different classes of hyaluronic acid (HA) (by molecular weight) or corticosteroid (ICS).</p><p><strong>Materials and methods: </strong>Patients across high molecular weight (HMW) HA, medium molecular weight (MMW) HA, low molecular weight (LMW) HA, and ICS therapy groups were matched from a U.S. claims database (Optum's de-identified Clinformatics Data Mart Database), with a final size of 6,234 patients per group. Adjusted six-month medical/prescription costs per patient per month (PPPM), and HCRU rates and costs, were determined. Secondary endpoints included complication rates and adjusted costs, new prescription analgesic use, and adjunctive/supplemental intra-articular treatment.</p><p><strong>Results: </strong>Mean adjusted PPPM medical costs were highest for LMW HA ($527.14), followed by HMW HA ($469.35) and MMW HA ($441.97) (<i>p</i> < .001), and lowest for the ICS group ($240.26; <i>p</i> < .001). Office visit, arthrocentesis, and subsequent ICS/arthrocentesis rates and corresponding costs, as well as costs for any complications, decreased from LMW HA to MMW HA to HMW HA. The ICS group had greater arthrocentesis, subsequent ICS/arthrocentesis, and office visit costs versus MMW and HMW HA groups. The ICS group had higher rates of new prescription analgesic use (15.8% versus 11.7%-12.2%) and adjunctive ICS (21.8% vs. 9.4%-11.1%) and HA (14.1% versus 1.6%-5.3%) treatment than the HA groups. HMW HA had the lowest rates of adjunctive non-index HA treatment.</p><p><strong>Limitations: </strong>Claims data contains limited clinical data and relied on the accuracy of coding of diagnoses and procedures.</p><p><strong>Conclusions: </strong>Among HA products, HMW HA may provide greater short-term clinical and economic benefits. Additionally, intra-articular HA therapy may provide improved short-term clinical and economic results over ICS, in terms of lower rates of adjunctive intra-articular treatments, HCRU, and new prescription analgesic use. Complication rates were low reflecting the safety profiles of HA and ICS.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"1334-1347"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144873581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public health impact and cost-effectiveness of implementing gender-neutral vaccination with a 9-valent HPV vaccine in Japan: a modeling study.","authors":"Cody Palmer, Taizo Matsuki, Keisuke Tobe, Xuedan You, Ya-Ting Chen","doi":"10.1080/13696998.2025.2520703","DOIUrl":"10.1080/13696998.2025.2520703","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed to assess the public health impact and cost-effectiveness of gender-neutral vaccination (GNV) using a nonavalent vaccine (9vHPV) in Japan.</p><p><strong>Methods: </strong>We used a published, validated dynamic transmission model to estimate the cases of, deaths from, quality-adjusted life years (QALYs) lost to, and costs of diseases associated with HPV genotypes included in the 9vHPV vaccine. These outcomes were modeled over a 100-year time horizon under different GNV and female-only vaccination (FOV) strategies. The primary analysis compared GNV to FOV at a female vaccination coverage rate (VCR) of 30% and male VCR of 15%. Scenario analyses assessed the effects of varying these VCRs, the age at vaccination, and the discount rate.</p><p><strong>Results: </strong>In the base case, GNV averted an additional 2,070 female and 1,773 male deaths from HPV-associated cancers compared to FOV and was cost effective, with an incremental cost-effectiveness ratio (ICER) of 4,798,537 ¥/QALY from the payer perspective (direct medical costs) and 4,248,586 ¥/QALY from the societal perspective (including costs of lost work productivity). The ICER of GNV versus FOV was higher in scenarios with higher VCRs. However, the ICER could be reduced compared to the base case by implementing vaccination at <15 years of age to reduce the number of vaccine doses required or by reducing the discount rate to assign greater value to the long-term cancer prevention benefits of HPV vaccination.</p><p><strong>Limitations: </strong>This study may be limited by inaccuracies in the model's input data and assumptions, as well as the exclusion of some societal costs, which may have underestimated cost-effectiveness.</p><p><strong>Conclusions: </strong>Including boys and men in Japan's HPV vaccination strategy is predicted to provide additional public health benefits compared to FOV and to be cost effective, particularly while the female VCR remains low and if the full vaccine series is completed before age 15.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":" ","pages":"974-985"},"PeriodicalIF":2.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statement of Retraction: Foslevodopa/foscarbidopa (LDp/CDp) in advanced Parkinson's Disease (aPD): demonstration of savings from a societal perspective in the UK.","authors":"","doi":"10.1080/13696998.2025.2558292","DOIUrl":"https://doi.org/10.1080/13696998.2025.2558292","url":null,"abstract":"","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"28 1","pages":"1500"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States.","authors":"Marika Hancock, Cayden Beyer, Michael Fuchs, Mukesh Harisinghani, Prasun Jalal, Michael Ndaa, Niharika Samala, Jose D Vargas, Arjun Jayaswal","doi":"10.1080/13696998.2025.2550113","DOIUrl":"10.1080/13696998.2025.2550113","url":null,"abstract":"<p><strong>Objective: </strong>The US Food and Drug Administration (FDA) recently approved the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), resmetirom, without clarifying the most effective strategy for diagnosing or monitoring response to therapy. Current standards-of-care (SoC) for Veterans Health Administration (VHA) and Medicare patients largely rely on vibration-controlled transient elastography (VCTE) and/or liver biopsy. Multiparametric MRI corrected T1 (cT1) is a cost-effective, noninvasive liver disease assessment (NILDA) tool in MASH. We evaluated the budgetary impact of pathways using cT1 versus SoC (liver biopsy or VCTE) to assign suspected MASH patients to resmetirom and for those assigned treatment, monitor response.</p><p><strong>Methods: </strong>A model of the VHA and Medicare populations was used to derive a budget impact comparing cT1, VCTE and liver biopsy. Clinical and cost data were taken from publicly available sources and used to estimate the number of patients prescribed resmetirom, the identification of those benefiting from therapy, the budgetary impact of each diagnosis and monitoring strategy and the cost of medication prescribed.</p><p><strong>Results: </strong>For the VHA, cT1 resulted in the lowest per-patient costs ($7,022 (cT1) vs $7,268 (liver biopsy) vs $28,509 (VCTE)), with results remaining consistent across scenario analyses. In the Medicare population, cT1 also resulted in the lowest per-patient costs ($11,866 (cT1) vs $15,488 (biopsy) vs $27,539 (VCTE)) and these results also remained consistent across scenario analyses.</p><p><strong>Conclusion: </strong>The use of cT1 to assign and monitor resmetirom treatment improves treatment allocation and reduces health system cost vs VCTE and liver biopsy.</p>","PeriodicalId":16229,"journal":{"name":"Journal of Medical Economics","volume":"28 1","pages":"1370-1387"},"PeriodicalIF":3.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144957377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}